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Abstract
Background: Lung cancer has been the main concern of the cancer-related deaths worldwide. Non-small cell lung
cancer (NSCLC) is reported the most common subtype of lung cancer. Initial staging of NSCLC is highly associated
with the choice of treatment and prognosis of the patients. This study aims to prospectively compare the diagnostic
efficacies of 64-multidetector-row computed tomography (MDCT) and 3.0 T magnetic resonance imaging (MRI) in
T staging of NSCLC.
Methods: Institutional review board approval and informed consent were obtained. Forty-five patients diagnosed with
NSCLC who underwent preoperative MRI and MDCT scans were enrolled in the study. The efficacies of determination
of T staging on MRI and MDCT were compared by using the McNemar test.
Results: Of 45 patients diagnosed with NSCLC, the primary tumors were correctly staged in 38 (84.4 %) patients
on MDCT, and in 37 (82.2 %) patients on MRI. There was no statistically significant difference between the two
modalities in the overall T staging of NSCLC with the reference of pathological findings (p = 0.564). However, MDCT
was indicated more accurate in determination of NSCLC staged T1 and T2 (100 % vs 75 %, 96.4 % vs 82.1 %), whereas
MRI was presented slightly superior in identification of NSCLC staged T3 and T4 (80 % vs 50 %, 100 % vs 33.3 %).
Conclusion: Both MDCT and MRI provided acceptable overall accuracies in determination of T staging in NSCLC.
Furthermore, MRI was presented slight superiority for the advanced-stage tumors (i.e., NSCLC staged T3 and T4),
whereas MDCT was indicated mild acceptance for the limited-stage tumors (i.e., NSCLC staged T1 and T2).
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Background
Lung cancer is one of the most common malignancies in
China, with the cancer-related deaths reported rapidly over
thirty years [1]. In 2008, lung cancer accounted for 14.5 %
of all newly diagnosed malignancies in the USA [2], 85% of
diagnosed lung cancers were non-small cell lung cancer
(NSCLC) [3]. Surgical resection remains the curable ap-
proach among the treatments of choice in the management
of NSCLC, despite the continuous improvement and
development in the theraputic treatments so far. Initial
TNM staging is important in the decision-making process
of management as well as in predicting prognosis of the
patients with NSCLC. [4].
Various imaging modalities have been used for
preoperative T staging of NSCLC. Computed tomog-
raphy (CT) has been considered as standard of reference
for preoperative evaluation of intrathoracic spread of
lung cancer [5]. However, the assessment of preoperative
T staging in lung cancer on CT is still not totally satisfy-
ing, owing to its limitations in evaluation of tumor inva-
sion into adjacent structures [6]. On the other hand,
magnetic resonance imaging (MRI) has been increasingly
utilized in preoperative staging of lung cancerdue to its
strength in excellent soft tissue contrast and high spatial
resolution [5]. The purpose of our study was to compare
the efficacies of 3.0-T MRI and 64-MDCT for determin-
ing T staging of NSCLC.
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The institutional review board approved this prospective
study, and written informed consent were obtained from
all patients. From July 2011 to February 2013, a total of
51 consecutive patients pathologically diagnosed with
NSCLC who underwent MRI and MDCT examinations
were enrolled in this study. Of these 51 patients, 6 were
excluded owing to the history of preoperative neoadjuvant
chemotherapy (n = 4) and intolerable claustrophobia oc-
curred during the scanning (n = 2). The remaining 45 pa-
tients (30 men and 15 women; age range, 32-70 years;
mean age, 56 years) were included in this study. MDCT
and MRI scans were performed within a 7-day interval for
each patient. Each case enrolled was imaged with an
extent from the thoracic inlet through the adrenal glands
either on MDCT or MRI.
Image acquisition
MR examinations were performed on a 3.0-T MR scanner
(SIGNA EXCITE HD, GE Medical Systems) with a dedi-
cated 8-channel coil array system. All the patients were per-
formed with serial sequences: axial T1-weighted fast spin
echo (FSE) (TR = 600-900 ms, TE = 5.8 ms, acquisition
matrix size = 288 × 192 pixels), axial, sagittal and coronal
breath-hold T2-weighted FSE (TR = 6000-8000 ms, TE =
85 ms, acquisition matrix size = 288 × 244 pixels), axial
breath-hold T2-weighted FSE with fat suppression (TR =
6000-8000 ms, TE = 85 ms, acquisition matrix size = 288 ×
244 pixels). Other scanning parameters included were as
follows: field of view = 36-38 cm, slice thickness = 7-8 mm
with a 1 mm interslice gap. Dynamic contrast-enhanced
MR images were obtained with a breath-hold T1-weighted
in-phase two-dimensional gradient-echo sequence (TR =
2.9 ms, TE = 1.3 ms, TI = 5.0 ms, field of view = 40-42 cm,
slice thickness = 4 mm with 0 mm interslice gap, acquisi-
tion matrix size = 288 × 192 pixels,flip angle = 15°). A bolus
of 20 ml gadolinium diethylene triaminepenta acetate
(Gd-DTPA) as the intravenous contrast agent was adminis-
tered for all patients at a rate of 3 ml/sec. Dynamic
contrast-enhanced MR scan was started 5 s after the
completion of the administration. Each scanning of three
continuous phases was obtained with breath-hold in 15 s,
and in between there was a 15 s internal. Totally 24
continuous phases of images were achieved in 4 min.
A64-MDCT scanner (GE LightSpeed VCT, GE Medical
System) was used in this study. The scanning parameters
were as follows: tube voltage of 120 kV, tube currents of
270 mA, detector configuration of 0.625 (detector colli-
mation) x 64 (detectors), reconstruction section thick-
ness of 1.25 mm, reconstruction section interval of
0.8 mm, rotation time of 0.6 s, and pitch of 0.984. A
bolus of iohexol used as intravenous contrast agent
was administered with intravenous infusion at a dose of
1.5 ml/kg body weight (average, 90-120 ml) at a rate of
3 ml/s. Contrast-enhanced CT images were obtained 35 s
after completion of the administration.
Imaging evaluation and reference standard
Images acquired on each modality including the multi-
plannar reconstruction images of MDCT (i.e., coronal and
sagittal images) were evaluated. Two groups of 3 experi-
enced radiologists (N.W., Y.H. and W.T., with 8-30 years
of experience in thoracic CT imaging; H.OY., L.L. and
M.L., with 5-20 years of experience in thoracic MRI) inter-
preted the MDCT manifestations and MR findings, re-
spectively. Consensus was achieved to make a final
decision when disagreement occurred between readers
inside the group. Readers in each group were aware the
patients were diagnosed with NSCLC, whereas blinded
to the manifestations of the opposite modality and
pathological findings. Intra- and extra-pulamonary ana-
tomic structures studied including the size of tumor, in-
volvement of adjacent organs or chest wall, and lung
metastases were evaluated according to the 7th Edition of
the TMN Classification for Lung and Pleural Tumors.
Visceral pleural invasion were identified as any contact
between the tumor and pleura with associated pleural
thickening or retraction, whereas the visualized extra-
pleural fat plane was present. The contact between the
mass and chest wall exceeding 3 cm or more, presence
of obtuse angle between the mass and the chest wall,
mass extending into the chest wall, loss of the extra-
pleural fat plane, and rib destruction were the criteria in
the assessment on chest wall invasion [7]. The following
criteria was used in the identification of mediastinal inva-
sion: extensive contact between the tumor and mediasti-
num, pleural and pericardial thickening, contact of 180° or
greater between the tumor and mediastinal central vessels,
and loss of the fat plane between the tumor and the medi-
astinal structures [8, 9]. The assessment of T staging then
was compared with the diagnosis proven by pathology for
each lesion.
Statistical analysis
Statistical analyses were performed with SPSS 13.0 soft-
ware. Accuracies of MRI and MDCT were calculated by
using the standard definitions. Confidence intervals (CIs)
were calculated for accuracy values on the basis of a 95 %
confidence level. The differences of accuracy between
MRI and MDCT were compared by using McNemar
test. p value less than 0.05 was considered statistically
significant.
Results
Seventeen primary tumors were developed from the central
areas (size range, 2.5-8.6 cm; mean size, 4.1 ± 1.6 cm) and
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28 were originated from peripheral zone (size range,
1.3-8.3 cm; mean size, 3.4 ± 1.7 cm). The tumors were con-
firmed with pneumonectomy (n = 7), lobectomy (n = 32),
and wedge-shaped resection (n = 6), respectively. These
45 patients were diagnosed with adenocarcinoma in 25,
squamous cell carcinoma in 18, large cell neuroendocrine
carcinoma in 2. T staging of the tumors were classified as
T1 in 4, T2 in 28, T3 in 10, and T4 in 3, respectively.
Surgical and pathological examinations of 45 patients
revealed a diagnosis of pleural invasion in 22 patients,
chest wall invasion in 4 patients, mediastinal invasion in
3 patients.Table 1 gives the clinical and pathological
characteristics of 45 patients diagnosed with NSCLC.
Of the 45 primary tumors, T stages were correctly diag-
nosed in 38 (84.4 %) (The numbers in parenthesis stand
for the accuracies, similarly hereinafter) patients (95 % CI:
64.2 %, 89.2 %) on MDCT, and in 37 (82.2 %) patients
(95 % CI: 72.8 %, 94.6 %) on MRI. Table 2 provides the re-
sults of T stages in 45 patients with NSCLC using MDCT
and MRI. Table 3 shows the comparison of efficacies of
MDCT and MRI in T staging of 45 patients with NSCLC.
Although no statistically significant difference was pre-
sented between the two modalities in the overall T staging
of NSCLC when compared with that on the pathological
findings (p = 0.564), MDCT was indicated more accurate
in determination of NSCLC staged T1 and T2 (100 % vs
75 %, 96.4 % vs 82.1 %) when compared with that on MRI,
whereas MRI was presented slightly superior in identifica-
tion of NSCLC staged T3 and T4 (80 % vs 60 %, 100 % vs
33.3 %) when compared with that on MDCT.
Secondary changes due to post-obstructive atelectasis or
pneumonia was found in 26 patients, among them 16
(61.5 %) patients (95 % CI: 43.9 %, 81.1 %) were identified
on MDCT, whereas 22 (84.6 %) patients (95 % CI: 70.7 %,
98.5 %) were determined on MRI (p = 0.014) (Fig. 1). Vis-
ceral pleural invasion of 22 cases was proved by surgical
and pathological findings, 16 cases were seen on MRI while
12 cases were reported on MDCT (p = 0.003) (Fig. 2). Four
cases were diagnosed with chest wall involvement on both
modalities (Fig. 3). Three cases presenting mediastinal
invasion were identified on MRI (Fig. 4); however, 2 of
these 3 cases were misinterpreted using MDCT. Evidence
of suspicious adrenal lesions was not noted in any case.
Discussion
In this study, it was demonstrated that both MDCT and
MRI provided acceptable overall accuracies in determin-
ation of T staging in the patients with NSCLC. Furthermore,
MRI was presented slight superiority for the advanced-stage
tumors (i.e., tumors staged T3 and T4), whereas MDCT
was indicated more accurate for the limited-stage tumors
(i.e., tumors staged T1 and T2) in the T staging of NSCLC.
Published research indicated that T staging in NSCLC
was more correctly determinated on MRI than that on CT
[10]. It was proved that 3.0 T MRI with the improved
signal-to-noise ratio and higher contrast resolution in soft
tissues combined with the application of phased-array car-
diac coils increased the diagnostic efficiency in the
Table 1 Clinical and Pathological Characteristics of 45 Patients
diagnosed with NSCLC
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Table 2 T staging of MDCT and MRI in 45 Patients with NSCLC
T staging MDCT MRI
T1 T2 T3 T4 T1 T2 T3 T4
T1 (n = 4) 4 0 0 0 3 1 0 0
T2 (n = 28) 1 27 0 0 2 23 3 0
T3 (n = 10) 0 3 6 1 0 2 8 0
T4 (n = 3) 0 1 1 1 0 0 0 3
Total (n = 45) 5 31 7 2 5 26 11 3
Table 3 Efficacies of MDCT and MRI for T Staging in 45 Patients
with NSCLC
T staging MDCT MRI P value
T1 (n = 4) 100 % (4/4) 75.0 % (3/4) /
T2 (n = 28) 96.4 % (27/28) 82.1 % (23/28) 0.480
T3 (n = 10) 60 % (6/10) 80 % (8/10) 0.157
T4 (n = 3) 33.3 %(1/3) 100 % (3/3) /
Total (n = 45) 84.4 % (38/45) 82.2 % (37/45) 0.564
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assessment of T staging of NSCLC [11]. In our study, the
overall accuracy for assessment of T staging in NSCLC on
CT and MRI was 84.4 % (38/45) and 82.2 % (37/45), re-
spectively, the difference between both modalities was not
statistically significant, and was similar to the study reported
by Yi et al, in which the primary tumors were correctly
staged in 101 (82 %) patients on integrated PET/CT and in
106 (86 %) patients on whole body 3.0 T MRI [10].
In our study, involvement of mediastinal pleura (in
that case tumor was staged with T3) of 2 cases were mis-
represented on MDCT, which caused the underestimation
of T staging in advanced tumor on MDCT, probably re-
lated to its relatively lower soft tissues contrast. Study has
proved that MRI was more useful for distinguishing T3
and T4 tumors from early staged diseases owing to the su-
perior contrast resolution [12]. One case of mediastinal
Fig. 1 Images of 64-year-old man with diagnosed squamous cell carcinoma of the left upper lung. The extent of primary tumor in the left hilum
(arrow) was not accurately distinguished from the secondary changes on axial MDCT (a). Tumor (arrow) was appeared as slightly hypointense
compared the signal of secondary changes on axial T2-weighted MRI (b). Tumor (arrow) was showed as hypointense while that of secondary
changes were hyperintense in early phase of dynamic contrast-enhanced MRI (c and d), in delay phase both of them were appeared as
heterogeneously hyperintanse (e and f)
Fig. 2 Images of 45-year-old woman with diagnosed adenocarcinoma of the right upper lung. Peripheral mass with associated pleural retraction
(arrow) was identified on axial MDCT (a and b), suggestive of pleural invasion (tumor staged T2). Extrapleural fat plane (arrow) was identified on
axial contrast-enhanced MRI (c). Pathology findings reported no evidence of visceral pleural involvement (tumor was staged T1)
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pleura invasion proven by pathology was missed on MRI.
It might be associated with the absence of cardiac-gated
T1-weighted sequence applied in our study, as with this
technique, MRI was considered being helpful in reducing
the cardiac motion artifact that significantly influenced the
evaluation of tumor involvement of areas of mediastinum
[13]. In addition, 1 case with false positive of invasion of
mediastinal pleura was occured on MRI, which might be
due to the challenge to distinguish tumor invasion from be-
nign inflammatory pleural adhesion on imaging modalities.
Contrast agents utilized in the developed MRI systems
have shown some advantage on the staging of NSCLC.
Previous research indicated that contrast-enhanced MRI
was more useful in assessment of cardiovascular and medi-
astinal invasion than that on MDCT [14], the comparable
sensitivity, specificity, and accuracy on MRI were reported
up to 90 %, 87 %, and 88 %, respectively. Even though the
advanced-stage cases included were limited, the advantages
of enhanced MRI were also noted in our study: 3 cases
associated with mediastinum invasion (presented as pul-
monary artery involvement in this study) were accurately
interpreted on MRI whereas only 1 of these cases was
identified on MDCT. On the other hand, MRI was widely
recognized to be more helpful in depicting tumor extent of
the lung cancer arising from the central areas owing to the
capability of MRI in distinguishing the tissues between the
tumor and the associated atelectasis or pneumonia [15], as
shown in the present study (p = 0.014). The signal repre-
senting primary tumor was noted significantly differed from
that of secondary atelectasis and pneumonia (i.e., tumor
manifested as hypointensity, whereas secondary changes
presented as hyperintensity) on early phase of dynamic
contrast-enhanced MRI. Four cases of central NSCLC with
secondary changes confirmed by pathology were not re-
vealed even on enhanced MRI, which might be related to
the obstructive changes in the affected bronchus caused by
limited-stage tumors were not sufficient to produce signifi-
cant reduction of the air flow in the corresponding airways
and lung tissues, thus were not visible on both modalities.
In this study, accuracy of diagnosis on determination of
visceral pleural invasion (in that case tumor was staged
with T2) assessed on MRI was statistically higher than that
Fig. 3 Images of 60-year-old man with adenocarcinoma of the left upper lung. Chest wall involvement (arrow) was identified on axial MDCT (a). Tumor
was presented as heterogeneous enhancement and was invading into the extrapleural fat plan (arrow) on saggital image of contrast-enhanced MRI (b)
Fig. 4 Images of 50-year-old woman with diagnosed adenocarcinoma of the left lung. Left pulmonary artery was visualized being encased with tumor
tissue at less than 180° (arrow) which indicated no involvement of the vessel on transverse MDCT (a). Transverse contrast-enhanced MR image showed
filling defect within the lumen of left pulmonary artery (arrow), caused the concern of tumor extending into the artery (b). The invasion was then
confirmed with pathology (tumor was staged T4)
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achieved on MDCT (p = 0.003). Although patient with
chest wall invasion (in that case tumor was staged with
T3) were used to the contraindication of surgical excision
for lung cancer, studies have suggested that selected pa-
tients with chest wall infiltration who underwent surgical
excision might be benefited with a better chance of
survival by developed surgical technologies [16, 17]. Infil-
tration into the extra pleural fat, an associated pleural
thickening, an obtuse angle, or more than 3 cm contact
with the pleura are thought to be the sensitive but non-
specific findings in the diagnosis of chest wall invasion,
the reliable manifestation suggestive of chest wall invasion
is rib bone destruction. Previous studies have shown that
sagittal and coronal MRI images with better tissue con-
trast resolution compared to that of CT were more effect-
ive in evaluating chest wall invasion [18, 19]. In this study,
4 cases of NSCLC presenting chest wall invasion were ac-
curately diagnosed on either MRI or MDCT, for the latter,
which might be contributed by the improved diagnostic
capability of MDCT with multiplanar reconstruction
capability [20]. For the case of superior sulcus tumor with
involvement of surrounding structures (e.g., vessels), MRI
has shown superiority of assessment of automatic rela-
tionship between the tumor and surrounding structure.
The distinction between tumors staged T3 and T4 on
imaging has considered being clinically significant as the T3
lesions are potentially resectable while T4 lesions are not.
In the present study, one tumor initially staged T4 on CT
was diagnosed as T3 on MRI which proven by pathology.
Furthermore, none of lesions staged T3 by pathology
misdiagnosed as T4 on MRI. However, two of 3 cases
staged T4 on MRI then proven by pathology were mis-
diagnosed on CT. For the patients with advanced-stage
diseases, accurate interpretation on imaging features might
improve the outcomes in the patients who were classified
as the candidates of surgery, and reduce the morbidity and
mortality rates in the ones who were treated with conserva-
tive approaches other than aggressive resection.
Selection bias is one of the major and common limita-
tions in the researches applied the study design similar to
that utilized in our study. Only three patients with primary
tumor staged T4 were enrolled, as pathological evidence
are only available for the patients who underwent oper-
ation on a potentially resectable stage of diseases. Only
eight tumors with a measurement less than 3 cm in size
were included in our study, as fewer patients referred to
our institution that a national cancer center in our country
presented early stage disease. Patients with certain positive
indicators which should be concerned in the staging of
lung cancer such as metastatic nodule were not included
in the study. Such selection bias had certain impact on the
evaluation of diagnostic accuracy in the present study;
further study characterized by an enlarged sample size
should be performed to confirm the validation.
Conclusions
In conclusion, both MDCT and MRI provided accept-
able accuracies in preoperative T staging of NSCLC.
Furthermore, MRI was presented slight superiority for
advanced-stage tumors (staged T3 and T4), whereas
MDCT was indicated mild acceptance for limited-stage
diseases (staged T1 and T2).
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